HD Immune GmbH Foundation and Publication of Latest Pre-Clinical Data

Contributed by: Business Wire

Tags

Research
Clinical Trials
Philanthropy
Biotechnology
Health
Fund Raising
Pharmaceutical
Foundation
Science
Huntington’s Disease

More Like This

Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome

Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome

Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington's Disease

PR Newswire associated0

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

PR Newswire associated0

Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease

PR Newswire associated0

Skyhawk Therapeutics Presents at Huntington's Disease Youth Organization HDYO International Congress 2025

PR Newswire associated0

ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference